UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **August 30, 2021**

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

001-35023	**26-2797813**
(Commission File Number)	*(IRS Employer Identification No.)*

8800 HSC Parkway
Bryan, TX 77807
(Address of principal executive offices and zip code)

(979) 446-0027
(Registrant's telephone number including area code)

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

IBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 is furnished with this Current Report on Form 8-K:

Exhibit Number	Description
99.1	Corporate Presentation of iBio, Inc. dated August 2021

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IBIO INC.

Date: August 30, 2021

By: /s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer

Growing A Next-Gen Biologics Pipeline

CORPORATE PRESENTATION: August 2021

Tom Isett, Chairman & CEO

Forward-Looking Statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines and RTX-003, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

iBio Snapshot

FastPharming®

- Sustainable manufacturing platform for next-gen biologics
- Expanding therapeutic pipeline focused in immuno-oncology and fibrotic diseases
- Platform enables rapid vaccine development
- Research & Bioprocess products create synergy with other business areas
- CDMO Services provide some cash flows
- Formidable patent estate protecting foundational technologies
- Expecting multiple catalysts over next 12 months
- Strong cash position, no debt



iBio

---

iBio's Platform Uses Plants for Bioprocessing; Enables Faster, Greener Drug Development

130,000sf FastPharming Facility



FastPharming Advantages

Speed | *Scalability* | *Sustainability* | *Safety*

iBio

iBio's *FastPharming* System Can Accelerate Drug Development

Concept to GMP Bulk Drug Substance



Acceleration supports earlier safety & stability studies prospectively enabling reduced time to IND

Mammalian timelines are for illustrative purposes only based upon competitive data from publicly available sources. Actual timelines may vary.

Growing Pipeline

Therapeutics:
Vaccines:

HUMAN HEALTH PROGRAMS								
THERAPEUTIC AREA	PROGRAM	INDICATION	DISCOVERY	LEAD OPTIMIZATION	PRE-CLINICAL	IND-ENABLING	PHASE I	PHASE II
Fibrosis	IBIO-100	Systemic Scleroderma[1]						
		Idiopathic Pulmonary Fibrosis						
Oncology	IBIO-101 (RTX-003)	Solid Tumors						
	Other Oncology	Undisclosed - Target 1						
		Undisclosed - Target 2						
		Undisclosed - Target 3						
Infectious Disease	ACE2-Fc	Acute Respiratory Distress Syndrome (ARDS)						
	IBIO-202	COVID-19 Subunit Vaccine						

ANIMAL HEALTH PROGRAMS					
	PROGRAM	INDICATION	POC	PRE-CLINICAL	CLINICAL DEV
Classic Swine Fever	IBIO-400	Classical Swine Fever Vaccine			

[1]Received Orphan Drug Designation from U.S. Food & Drug Administration



Oncology
Fibrosis
Infectious Diseases

Focusing New Drug Discovery Capabilities on Immuno-Oncology

RubrYc Transaction Provides Multiple Potential Sources of Value

RubrYc™ THERAPEUTICS

iBio

Exclusive Global License to RTX-003, a "second generation" anti-CD25 monoclonal antibody candidate for treatment of solid tumors

Discovery Collaboration providing iBio with access to the ***RubrYc*** AI Discovery Engine and new antibodies developed partnership

Equity Stake in RubrYc providing prospective future benefit from machine learning antibody discovery technology

THERAPEUTICS

iBio

"AI" – Artificial Intelligence

RTX-003 Stimulates Anti-tumor Immunity via anti-CD25 T_{reg} Depletion



1st gen CD25 mAbs depleted immuno-suppressive T_{reg} and immuno-stimulatory T_{eff}

Limited efficacy



2nd gen RTX-003 selectively targets T_{regs} without blocking IL-2 signaling to T_{effs}

Strong preclinical anti-tumor response

THERAPEUTICS

iBio

T_{reg} = Regulatory T Cells; T_{eff} = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity

RTX-003 Preclinical Data

RTX-003 potently binds CD25



and depleting T_{regs}



while preserving IL-2 signaling



while sparing T_{effs}



THERAPEUTICS

iBio

RTX-003 Inhibits Tumor Growth

Lymphoma Xenograft Model



THERAPEUTICS

RTX-003 reduced tumor growth in a dose-dependent manner

iBio

In vivo xenograft mouse model of lymphoma: Administration: 3x / week, i.p.; n=5 per group

RTX-003 in Combination with Checkpoint Inhibitors

Adenocarcinoma Model



THERAPEUTICS

RTX-003 + anti-PD-1 antibody reduced tumor growth and caused regression

iBio

in vivo transgenic hCD25 mouse model: RTX-003 was administered i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2.5 mg/Kg of anti-mouse PD-1 antibody; n=5/group

iBio Gains Access to RubrYc AI-Driven Discovery Platform

- RubrYc uses proprietary predictive algorithms to generate Meso-scale Engineered Molecules (MEMs)
- MEMs are subdominant epitope sequences, transplanted on structural proteins that allow the correct folding of the epitopes
- Result = Discovery of better antibodies



THERAPEUTICS

iBio

Fibrotic & Infectious Diseases



IBIO-100 for the treatment of fibrotic disorders

ACE2-Fc as a prospective COVID-19 program

THERAPEUTICS

iBio

IBIO-100 Promising Therapeutic Candidate for Fibrosis

Fibrotic Disorders

- Involved in ~45% of U.S. deaths from all diseases
- No cures: organ transplants for some late-stage diseases
- Limited number of palliative treatments for most indications
- Many patients forego currently available treatments due to poor tolerability
- Market for current drugs for idiopathic pulmonary fibrosis alone is presently >$1.8B*

IBIO-100

Collagen Derivative



Description

Endostatin E4 peptide that reduces fibrosis by impacting extracellular matrices

Pre-clinical data shows reduced fibrosis in scleroderma/IPF models & human lung explants

Orphan Drug Designation for systemic scleroderma received

Intrinsic properties could enable an oral route-of-administration

THERAPEUTICS

iBio

*Idiopathic Pulmonary Fibrosis: Disease Landscape & Forecast, Decision Resources, April 6, 2020

IBIO-100 Demonstrated Compelling Pre-Clinical Proof Of Concept

1. Compelling pre-clinical data
   - **Human lung explants**:
     - Demonstrates efficacy in Systemic Scleroderma (SSc) and Idiopathic Pulmonary Fibrosis (IPF) diseased human tissue
     - Note that explant tissue is so far compromised by disease that it needs to be removed for transplant
   - **Bleomycin mouse model**: Significant reduction of fibrotic tissue

2. IND-enabling studies for systemic scleroderma expected to commence during FY2022

Human Lung Tissue From End-Stage Disease at Transplant



Bleomycin Pre-Clinical Model



Fibrotic Tissue | 100µg IBIO-100 3x/week

THERAPEUTICS

ACE-F2C: Potential COVID-19 Therapeutic

iBio In-Licensed Worldwide Rights for Coronaviridae

- ACE2-Fc is a recombinant protein comprised of human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment (Fc)
- Molecule targets the coronavirus virions by using the ACE2 extracellular domain to bind the spike protein and block infection of healthy cells, while the fused Fc domain prolongs the life of the protein in circulation
- Benefits of a traditional neutralizing antibody, while prospectively limiting the potential for "viral escape"
- Planet's *in vitro* studies demonstrated that ACE2-Fc blocks SARS-CoV-2 virus from infecting Vero E6 cells
- Continuing to assess the regulatory and competitive landscape



Source: NEXU Science Communication | Reuters

THERAPEUTICS

COVID-19
Classic Swine Fever

IBIO-202 Demonstrated Potential to Raise Antibodies and Prime T-Cells for COVID in Preclinical Studies



Mice were immunized with iBio's SARS-CoV-2 nucleocapsid (N) vaccine candidate in combination with several adjuvants, leading to robust and differentiated immune responses. Th-1 skewed N-specific antibody titers were observed in antigen/adjuvant combinations following intramuscular injection, notably Groups 4 and 7 (panel A). Robust T cell priming was measured by ELIspot for multiple antigen/adjuvant combinations (C and D, as examples), while immune cells from a naïve mouse showed no response to exposure to the N antigen (B).

IBIO-202 Could Be Complementary To Current and Future S-Protein Vaccines

The N-protein:

- is abundantly expressed during infection
- contains immunogenic epitopes
- is more highly conserved than the S protein among the viral variants – new viral variants may be less likely to escape vaccine protection if vaccines include conserved sequences.[1,2,3,4]
- is significantly more effective than S protein in stimulating antibody-dependent natural killer cell activation, a critical element of the adaptive immune response that the SARS-CoV-2 virus attempts to evade[5]

Adjuvanted to potentially allow for greater immunogenicity and/or dose sparing

An "N-only" vaccine may be highly complementary to existing first-generation, S protein–directed vaccines

Prospectively suitable for delivery via routes other than intramuscular injection

The antigen is produced in our rapidly scalable ***FastPharming*** System

1. Zhao, P. et al. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331, 128–136 (2005).
2. Oliveira, S. C., de Magalhães, M. T. Q. & Homan, E. J. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. Front. Immunol. 11, (2020).
3. Dutta, N. K., Mazumdar, K. & Gordy, J. T. The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development. Journal of Virology 94, (2020).
4. Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nature Reviews Immunology 21, 73–82 (2021).
5. Fielding CA, Sabberwal P, Williamson JC, Greenwood EJD, Crozier TWM, Zelek W, Seaman J, Graham C, Huettner I, Edgeworth JD, Morgan BP, Ladell K, Eberl M, Humphreys IR, Wilkie S, Doores K, Wilson SJ, Lehner PJ, Wang ECY, Stanton RJ. ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies. bioRxiv. (April 2021)

iBio's "DAVi" Strategy Focuses on Attempting to Solve Multiple Challenges with Current COVID-19 Vaccines



IBIO-400: Classical Swine Fever Vaccine

Unmet Need

- Current CSF vaccines either cannot differentiate infected from vaccinated animals (DIVA) or are expensive
- CSF is a priority U.S. agricultural biothreat – as such, better vaccines are need to reduce risk to the $7B US pork export market

iBio's Approach

- iBio is using the ***FastPharming*** System to produce an E2 antigen, which may ultimately result in a DIVA-capable subunit vaccine (IBIO-400)
- We are seeking USDA approval for both the vaccine, and the ***FastPharming*** Facility in Bryan, Texas, and have filed an "Outline of Production" to the USDA for review

FastPharming-produced E2 glycoprotein single-dose vaccine protects pigs against classical swine fever



VACCINES

1 Richard C. Laughlin et al. 2018. Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever.

Still Growing CDMO Services while Transforming the Business

New/Enhanced Offerings

Glycaneering™ Development Services

Multi-Attribute BioAnalytics

CDMO SERVICES

CDMO Services

PD

Factory Sol'ns

Mfg

BioAnalytics

Fill-Finish

New Research and Bioproducts Offerings Launched



Summary

---

iBio, By the Numbers

Summary

2 complimentary segments with growth opportunities

Biopharm pipeline with **7** programs + discovery capability

$2M revenues from relaunched CDMO services

Cash reserves of **~$90M** fuels business into 2023

~80 employees (2x v. PY)

Transformation of plants into high-productivity bioreactors via infiltration

---

Management Team with Diverse Experience

Tom Isett
CEO & Chairman

GE · Lonza · BD · commence bio · i.e. Advising

Martin Brenner, DVM, Ph.D.
CSO

PFENEX · AstraZeneca · Lilly · MERCK · Pfizer

Robert Lutz, MBA
CFBO

STRONGBRIDGE BIOPHARMA · Shire · Goldman Sachs

Randy Maddux, MBA
COO

Aptevo Therapeutics · gsk · HGS · Biogen

Lisa Middlebrook
CHRO

LUPIN · Lonza

Anticipated Pipeline Milestones – Next 12 Months

HUMAN HEALTH	
Program	**Milestones**
IBIO-100	IND-enabling study initiation
IBIO-101	IND-enabling study initiation
ACE2-Fc	Competitive and regulatory assessment
IBIO-202	Intramuscular and intranasal preclinical study results

ANIMAL HEALTH	
Program	**Milestones**
IBIO-400	Efficacy Study Results USDA approval - Outline of Production

Strong and Growing IP Estate Provides Exclusivity for iBio's Pipeline

102
Issued Patents
(30 U.S.)

19
Active Applications
(7 U.S.)

→ **More Applications** progressing to filing

Patent Protection includes:

- IP for iBio's pipeline products and vaccines
- IP related to the ***FastPharming*** Protein Expression System®
- Elements of ***Glycaneering*** Technology Platform for advanced glycosylation controls in plants, including afucosylation for Antibody-Dependent Cellular Cytotoxicity (ADCC)

Financial Overview

Publicly traded (NYSEA: IBIO) since January 2008

Approximately $103.9 million in cash and cash equivalents plus investments in debt securities as of 31 March 2021

Current cash provides a runway at least through March 2023

Approximately 216.0 million common shares and approximately 5.7 million options and restricted stock units to purchase shares of common stock outstanding as of 31 March 2021

No debt